{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T05:09:45Z","timestamp":1794373785331,"version":"4.9.0"},"reference-count":37,"publisher":"Ferrata Storti Foundation (Haematologica)","issue":"8","license":[{"start":{"date-parts":[[2022,1,13]],"date-time":"2022-01-13T00:00:00Z","timestamp":1642032000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["haematol"],"abstract":"<jats:p>Whether corticosteroids improve outcome in patients with acute complications of sickle cell disease (SCD) is still debated. We performed a systematic review of the literature with the aim of estimating effects of corticosteroids on the clinical course of vaso-occlusive crisis (VOC) or acute chest syndrome (ACS) in patients with SCD. The primary outcome was transfusion requirement during hospitalization. Studies were identified by search of MEDLINE and CENTRAL database. Three randomized clinical trials (RCT) and three retrospective cohort studies (RCS) were included, involving 3,304 participants and 5,562 VOC or ACS episodes. There was no difference between corticosteroids and standard treatment regarding transfusion requirement overall (odds ratio [OR]=0.98, 95% confidence interval [CI]: 0.38-2.53) but there was a significant interaction of the study type (P&lt;0.0001): corticosteroid therapy was associated with a lower risk of transfusion in RCT (OR=0.13, 95% CI: 0.04-0.45) and a higher risk of transfusion in RCS (OR=2.12, 95% CI: 1.33-3.40. In RCT, the length of hospital stay was lower with corticosteroids as compared with standard treatment: mean difference - 24 hours (95% CI: -35 to -14). Corticosteroids were associated with an increased risk of hospital readmission as compared with standard treatment, in RCT, RCS, and the entire cohort: OR=5.91, 95% CI: 1.40-24.83; OR=3.28, 95% CI: 1.46-7.36 and OR=3.21, 95% CI: 1.97-5.24, respectively. Corticosteroids were associated with reduced number of transfusions and length of stay in RCT but not in RCS, with more rehospitalizations overall. Additional RCT should be conducted while minimizing the risk of rehospitalizations.<\/jats:p>","DOI":"10.3324\/haematol.2021.280105","type":"journal-article","created":{"date-parts":[[2022,1,13]],"date-time":"2022-01-13T02:35:22Z","timestamp":1642041322000},"page":"1914-1921","source":"Crossref","is-referenced-by-count":20,"title":["Effects of corticosteroids in patients with sickle cell disease and acute complications: a systematic review and meta-analysis"],"prefix":"10.3324","volume":"107","author":[{"given":"Julien","family":"Lopinto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Segolene","family":"Gendreau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enora","family":"Berti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pablo","family":"Bartolucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anoosha","family":"Habibi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Armand Mekontso","family":"Dessap","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1856","published-online":{"date-parts":[[2022,1,13]]},"reference":[{"key":"38738","doi-asserted-by":"crossref","unstructured":"Ballas SK, Lusardi M Hospital readmission for adult acute sickle cell painful episodes: frequency, etiology, and prognostic significance. Am J Hematol. 2005; 79(1):17-25.","DOI":"10.1002\/ajh.20336"},{"key":"38739","doi-asserted-by":"crossref","unstructured":"Booth C, Inusa B, Obaro SK. Infection in sickle cell disease: a review. Int J Infect Dis IJID Off Publ Int Soc Infect Dis. 2010; 14(1):e2-e12.","DOI":"10.1016\/j.ijid.2009.03.010"},{"key":"38740","doi-asserted-by":"crossref","unstructured":"Vichinsky EP, Neumayr LD, Earles AN. Causes and outcomes of the acute chest syndrome in sickle cell disease. National Acute Chest Syndrome Study Group. N Engl J Med. 2000; 342(25):1855-1865.","DOI":"10.1056\/NEJM200006223422502"},{"key":"38741","doi-asserted-by":"crossref","unstructured":"Kato GJ, Steinberg MH, Gladwin MT. Intravascular hemolysis and the pathophysiology of sickle cell disease. J Clin Invest. 2017; 127(3):750-760.","DOI":"10.1172\/JCI89741"},{"key":"38742","doi-asserted-by":"crossref","unstructured":"Belcher JD, Mahaseth H, Welch TE. Critical role of endothelial cell activation in hypoxia-induced vasoocclusion in transgenic sickle mice. Am J Physiol-Heart Circ Physiol. 2005; 288(6):H2715-H2725.","DOI":"10.1152\/ajpheart.00986.2004"},{"key":"38743","doi-asserted-by":"crossref","unstructured":"Okpala I. Leukocyte adhesion and the pathophysiology of sickle cell disease. Curr Opin Hematol. 2006; 13(1):40-44.","DOI":"10.1097\/01.moh.0000190108.62414.06"},{"key":"38744","doi-asserted-by":"crossref","unstructured":"Stuart MJ, Setty BN. Sickle cell acute chest syndrome: pathogenesis and rationale for treatment. Blood. 1999; 94(5):1555-1560.","DOI":"10.1182\/blood.V94.5.1555"},{"key":"38745","doi-asserted-by":"crossref","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG, Group TP. Preferred reporting items for systematic reviews and meta-analyses: The PRISMA Statement. PLoS Med. 2009; 6(7):e1000097.","DOI":"10.1371\/journal.pmed.1000097"},{"key":"38746","doi-asserted-by":"crossref","unstructured":"Savovi\u0107 J, Weeks L, Sterne JAC. Evaluation of the Cochrane Collaboration\u2019s tool for assessing the risk of bias in randomized trials: focus groups, online survey, proposed recommendations and their implementation. Syst Rev. 2014; 3:37.","DOI":"10.1186\/2046-4053-3-37"},{"key":"38747","doi-asserted-by":"crossref","unstructured":"Page MJ, McKenzie JE, Higgins JPT. Tools for assessing risk of reporting biases in studies and syntheses of studies: a systematic review. BMJ Open. 2018; 8(3):e019703.","DOI":"10.1136\/bmjopen-2017-019703"},{"key":"38748","doi-asserted-by":"crossref","unstructured":"Sterne JA, Hern\u00e1n MA, Reeves BC. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ. 2016; 355:i4919.","DOI":"10.1136\/bmj.i4919"},{"key":"38749","doi-asserted-by":"crossref","unstructured":"McGuinness LA, Higgins JPT. Risk-of-bias VISualization (robvis): An R package and Shiny web app for visualizing risk-of-bias assessments. Res Synth Methods. 2021; 12(1):55-61.","DOI":"10.1002\/jrsm.1411"},{"key":"38750","doi-asserted-by":"crossref","unstructured":"Wan X, Wang W, Liu J, Tong T Estimating the sample mean and standard deviation from the sample size, median, range and\/or interquartile range. BMC Med Res Methodol. 2014; 14:135.","DOI":"10.1186\/1471-2288-14-135"},{"key":"38751","doi-asserted-by":"crossref","unstructured":"Higgins JPT, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002; 21(11):1539-1558.","DOI":"10.1002\/sim.1186"},{"key":"38752","doi-asserted-by":"crossref","unstructured":"Sedgwick P. Meta-analyses: heterogeneity and subgroup analysis. BMJ. 2013; 346:f4040.","DOI":"10.1136\/bmj.f4040"},{"key":"38753","doi-asserted-by":"crossref","unstructured":"Isakoff MS, Lillo JA, Hagstrom JN. A single-institution experience with treatment of severe acute chest syndrome: lack of rebound pain with dexamethasone plus transfusion therapy. J Pediatr Hematol Oncol. 2008; 30(4):322-325.","DOI":"10.1097\/MPH.0b013e3181647bb2"},{"key":"38754","doi-asserted-by":"crossref","unstructured":"Yeral M, Boga C, Aytan P, Ozdogu H Corticosteroid-induced vaso-occlusive events may be prevented by lowering hemoglobin S levels in adults with sickle cell disease. Transfus Apher Sci. 2017; 56(5):717-718.","DOI":"10.1016\/j.transci.2017.08.005"},{"key":"38755","doi-asserted-by":"crossref","unstructured":"Sobota A, Graham DA, Neufeld EJ, Heeney MM. Thirty-day readmission rates following hospitalization for pediatric sickle cell crisis at freestanding children\u2019s hospitals: Risk factors and hospital variation. Pediatr Blood Cancer. 2012; 58(1):61-65.","DOI":"10.1002\/pbc.23221"},{"key":"38756","doi-asserted-by":"crossref","unstructured":"Griffin TC, McIntire D, Buchanan GR. High-dose intravenous methylprednisolone therapy for pain in children and adolescents with sickle cell disease. N Engl J Med. 1994; 330(11):733-737.","DOI":"10.1056\/NEJM199403173301101"},{"key":"38757","doi-asserted-by":"crossref","unstructured":"Bernini JC, Rogers ZR, Sandler ES, Reisch JS, Quinn CT, Buchanan GR. Beneficial effect of intravenous dexamethasone in children with mild to moderately severe acute chest syndrome complicating sickle cell disease. Blood. 1998; 92(9):3082-3089.","DOI":"10.1182\/blood.V92.9.3082.421k15_3082_3089"},{"key":"38758","doi-asserted-by":"crossref","unstructured":"Quinn CT, Stuart MJ, Kesler K. Tapered oral dexamethasone for the acute chest syndrome of sickle cell disease: Short Report. Br J Haematol. 2011; 155(2):263-267.","DOI":"10.1111\/j.1365-2141.2011.08827.x"},{"key":"38759","doi-asserted-by":"crossref","unstructured":"Strouse JJ, Takemoto CM, Keefer JR, Kato GJ, Casella JF. Corticosteroids and increased risk of readmission after acute chest syndrome in children with sickle cell disease: acute chest syndrome in sickle cell disease. Pediatr Blood Cancer. 2008; 50(5):1006-1012.","DOI":"10.1002\/pbc.21336"},{"key":"38760","doi-asserted-by":"crossref","unstructured":"Kumar R, Qureshi S, Mohanty P, Rao SP, Miller ST. A short course of prednisone in the management of acute chest syndrome of sickle cell disease. J Pediatr Hematol Oncol. 2010; 32(3):e91-94.","DOI":"10.1097\/MPH.0b013e3181c29c52"},{"key":"38761","doi-asserted-by":"crossref","unstructured":"Sobota A, Graham DA, Heeney MM, Neufeld EJ. Corticosteroids for acute chest syndrome in children with sickle cell disease: variation in use and association with length of stay and readmission. Am J Hematol. 2010; 85(1):24-28.","DOI":"10.1002\/ajh.21565"},{"key":"38762","doi-asserted-by":"crossref","unstructured":"Habibi A, Arlet J-B, Stankovic K. [French guidelines for the management of adult sickle cell disease: 2015 update]. Rev Med Interne. 2015; 36(5 Suppl 1):5S3-84.","DOI":"10.1016\/S0248-8663(15)60002-9"},{"key":"38763","doi-asserted-by":"crossref","unstructured":"Cooper TE, Hambleton IR, Ballas SK, Johnston BA, Wiffen PJ. Pharmacological interventions for painful sickle cell vasoocclusive crises in adults. Cochrane Database Syst Rev. 2019; 2019(11):CD012187.","DOI":"10.1002\/14651858.CD012187.pub2"},{"key":"38764","doi-asserted-by":"crossref","unstructured":"Dunlop RJ, Bennett KCLB. Pain management for sickle cell disease. Cochrane Database Syst Rev. 2006; 2:CD003350.","DOI":"10.1002\/14651858.CD003350.pub2"},{"key":"38765","unstructured":"Meremikwu MM, Okomo U Sickle cell disease. BMJ Clin Evid. 2016; 2016:2402."},{"key":"38766","doi-asserted-by":"crossref","unstructured":"Dolatkhah R, Dastgiri S Blood transfusions for treating acute chest syndrome in people with sickle cell disease. Cochrane Database Syst Rev. 2020; 1(1):CD007843.","DOI":"10.1002\/14651858.CD007843.pub4"},{"key":"38767","doi-asserted-by":"crossref","unstructured":"Ogunlesi F, Heeney MM, Koumbourlis AC. Systemic corticosteroids in acute chest syndrome: friend or foe?. Paediatr Respir Rev. 2014; 15(1):24-27.","DOI":"10.1016\/j.prrv.2013.10.004"},{"key":"38768","doi-asserted-by":"crossref","unstructured":"Vandy Black L, Smith WR. Evidence-based mini-review: are systemic corticosteroids an effective treatment for acute pain in sickle cell disease?. Hematol Am Soc Hematol Educ Program. 2010; 2010(1):416-417.","DOI":"10.1182\/asheducation-2010.1.416"},{"key":"38769","doi-asserted-by":"crossref","unstructured":"RECOVERY Collaborative Group, Horby P, Lim WS. Dexamethasone in hospitalized patients with Covid-19 -preliminary report. N Engl J Med. 2021; 384(8):693-704.","DOI":"10.1056\/NEJMoa2021436"},{"key":"38770","doi-asserted-by":"crossref","unstructured":"Couillard S, Benkerrou M, Girot R, Brousse V, Ferster A, Bader-Meunier B Steroid treatment in children with sickle-cell disease. Haematologica. 2007; 92(3):425-426.","DOI":"10.3324\/haematol.10800"},{"key":"38771","doi-asserted-by":"crossref","unstructured":"Darbari DS, Fasano R s., Minniti CP. Severe Vaso-occlusive episodes associated with use of systemic corticosteroids in patients with sickle cell disease. J Natl Med Assoc. 2008; 100(8):948-951.","DOI":"10.1016\/S0027-9684(15)31410-3"},{"key":"38772","doi-asserted-by":"crossref","unstructured":"Mishler JM, Emerson PM. Development of neutrophilia by serially increasing doses of dexamethasone. Br J Haematol. 1977; 36(2):249-257.","DOI":"10.1111\/j.1365-2141.1977.tb00646.x"},{"key":"38773","doi-asserted-by":"crossref","unstructured":"Liem RI, O\u2019Gorman MR, Brown DL. Effect of red cell exchange transfusion on plasma levels of inflammatory mediators in sickle cell patients with acute chest syndrome. Am J Hematol. 2004; 76(1):19-25.","DOI":"10.1002\/ajh.20054"},{"key":"38774","doi-asserted-by":"crossref","unstructured":"Strouse JJ, Hulbert ML, DeBaun MR, Jordan LC, Casella JF. Primary hemorrhagic stroke in children with sickle cell disease is associated with recent transfusion and use of corticosteroids. Pediatrics. 2006; 118(5):1916-1924.","DOI":"10.1542\/peds.2006-1241"}],"container-title":["Haematologica"],"original-title":[],"link":[{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2021.280105\/74055","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2021.280105\/74702","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/10501\/74055","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:00:52Z","timestamp":1794045652000},"score":1,"resource":{"primary":{"URL":"https:\/\/haematologica.org\/article\/view\/haematol.2021.280105"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,13]]},"references-count":37,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2022,8,1]]}},"URL":"https:\/\/doi.org\/10.3324\/haematol.2021.280105","relation":{},"ISSN":["1592-8721","0390-6078"],"issn-type":[{"value":"1592-8721","type":"electronic"},{"value":"0390-6078","type":"print"}],"subject":[],"published":{"date-parts":[[2022,1,13]]}}}